Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium (Q33384992)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium |
scientific article |
Statements
1 reference
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium (English)
1 reference
John D Hainsworth
1 reference
Tiffanie M Markus
1 reference
David R Spigel
1 reference
Dianna Shipley
1 reference
Dana Thompson
1 reference
Richard Rotman
1 reference
Charles Dannaher
1 reference
F Anthony Greco
1 reference
1 reference
Identifiers
1 reference